These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 25721557)

  • 1. Effectiveness and safety of therapy with vitamin K antagonists in Italian patients aged 80 years or older: a multicentre retrospective study comparing the Zeus algorithm with the PARMA algorithm or manual therapy.
    Cafolla A; Manisco L; Baldacci E; Porcu A; Campanelli M; Cursano MC; Rossi E; Dragoni F; Foà R
    Drugs Aging; 2015 Mar; 32(3):235-41. PubMed ID: 25721557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Zeus" a new oral anticoagulant therapy dosing algorithm: a cohort study.
    Cafolla A; Melizzi R; Baldacci E; Pignoloni P; Dragoni F; Campanelli M; Caraccini R; Foà R
    Thromb Res; 2011 Oct; 128(4):325-30. PubMed ID: 21600633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Frequency of use of oral vitamin K antagonists in patients with atrial fibrillation and cognitive function disturbances].
    Gorzelak P; Zyzak S; Krewko Ł; Mozdzan M; Broncel M
    Pol Merkur Lekarski; 2014 May; 36(215):302-6. PubMed ID: 24964505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New oral anticoagulants for the prevention of thromboembolic complications in atrial fibrillation: a single centre experience.
    Gorczyca-Michta I; Wożakowska-Kapłon B
    Kardiol Pol; 2015; 73(2):85-93. PubMed ID: 25179482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Time in therapeutic range (TTR) and follow-up of patients on vitamin K antagonist: A cohort analysis].
    Valdelièvre E; Quéré I; Caré B; Laroche JP; Schved JF
    J Med Vasc; 2018 May; 43(3):155-162. PubMed ID: 29754725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial.
    ; Bousser MG; Bouthier J; Büller HR; Cohen AT; Crijns H; Davidson BL; Halperin J; Hankey G; Levy S; Pengo V; Prandoni P; Prins MH; Tomkowski W; Torp-Pedersen C; Wyse DG
    Lancet; 2008 Jan; 371(9609):315-21. PubMed ID: 18294998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation.
    Lip GYH; Haguenoer K; Saint-Etienne C; Fauchier L
    Chest; 2014 Sep; 146(3):719-726. PubMed ID: 24722973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial.
    De Caterina R; John Camm A
    Europace; 2016 Jan; 18(1):6-11. PubMed ID: 26450845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of genetic and clinical factors on dose requirements and quality of anticoagulation therapy in Polish patients receiving acenocoumarol: dosing calculation algorithm.
    Wolkanin-Bartnik J; Pogorzelska H; Szperl M; Bartnik A; Koziarek J; Bilinska ZT
    Pharmacogenet Genomics; 2013 Nov; 23(11):611-8. PubMed ID: 24108193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of oral anticoagulation with non-vitamin K antagonists compared to well-managed vitamin K antagonists in naïve patients with non-valvular atrial fibrillation: Propensity score matched cohort study.
    Denas G; Gennaro N; Ferroni E; Fedeli U; Saugo M; Zoppellaro G; Padayattil Jose S; Costa G; Corti MC; Andretta M; Pengo V
    Int J Cardiol; 2017 Dec; 249():198-203. PubMed ID: 28935464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation of the SAMe-TT2R2 score to quality of anticoagulation control and thromboembolic events in atrial fibrillation patients: Observations from the SPORTIF trials.
    Proietti M; Lane DA; Lip GY
    Int J Cardiol; 2016 Aug; 216():168-72. PubMed ID: 27156060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in knowledge among patients with atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants and vitamin K antagonists.
    Konieczyńska M; Sobieraj E; Bryk AH; Dębski M; Polak M; Podolec P; Małecka B; Pająk A; Desteghe L; Heidbuchel H; Undas A
    Kardiol Pol; 2018; 76(7):1089-1096. PubMed ID: 29528483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between Mediterranean diet and time in therapeutic range in atrial fibrillation patients taking vitamin K antagonists.
    Pignatelli P; Pastori D; Vicario T; Bucci T; Del Ben M; Russo R; Tanzilli A; Nardoni ML; Bartimoccia S; Nocella C; Ferro D; Saliola M; Cangemi R; Lip GY; Violi F
    Europace; 2015 Aug; 17(8):1223-8. PubMed ID: 25995397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina.
    Tajer C; Ceresetto J; Bottaro FJ; Martí A; Casey M;
    Clin Appl Thromb Hemost; 2017 Jul; 23(5):445-453. PubMed ID: 26739542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
    De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
    Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin K antagonists in patients with nonvalvular atrial fibrillation: appropriateness and quality of treatment in an Italian cohort.
    Pereira de Sousa L; Burba I; Ruperto C; Lattuada L; Barbone F; Di Chiara A
    J Cardiovasc Med (Hagerstown); 2013 Jul; 14(7):534-40. PubMed ID: 23328227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Decisional algorithm to prescribe vitamin K antagonist in geriatric patients with atrial fibrillation].
    Sibai MS; Bellarbre F; Ghazali N; Bureau ML; Priner M; Ingrand P; Paccalin M
    Geriatr Psychol Neuropsychiatr Vieil; 2014 Mar; 12(1):20-4. PubMed ID: 24647235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study.
    Buller HR; Halperin J; Hankey GJ; Pillion G; Prins MH; Raskob GE
    J Thromb Haemost; 2014 Jun; 12(6):824-30. PubMed ID: 24597472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.